Phaseline

Companies › LaNova Medicines

LaNova Medicines: clinical trials, targets and expected readouts

7 active drug programs in 10 registered trials: 7 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LM-108
Anti-CCR8 monoclonal antibody
CCR8Phase 3Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Advanced Solid TumorAug 2028
LM-24C5
Anti-CEACAM5 antibody or antibody-drug conjugate
CEACAM5Phase 2Advanced Solid Tumor Cancer; Advanced Solid TumorDec 2026
LM-168–Phase 2Advanced Solid Tumor; Advanced Solid TumoursAug 2027
LM-299–Phase 1Malignant TumorsDec 2026
LM-101–Phase 1Malignant TumorsJan 2027
LM-350–Phase 1Malignant TumorsJun 2028
LM-2417–Phase 1Advanced Solid TumorDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05518045LM-108Phase 1Advanced Solid TumorOncologyOct 2026
NCT06650566LM-299Phase 1Malignant TumorsOncologyDec 2026
NCT06187402LM-24C5Phase 1Advanced Solid TumorOncologyDec 2026
NCT05615974LM-101Phase 1Malignant TumorsOncologyJan 2027
NCT06868199LM-168Phase 1Advanced Solid TumoursOncologyAug 2027
NCT07669415LM-168Phase 2Advanced Solid TumorOncologyDec 2027
NCT07387081LM-24C5Phase 2Advanced Solid Tumor CancerOncologyMay 2028
NCT07112222LM-350Phase 1Malignant TumorsOncologyJun 2028
NCT07362186LM-108Phase 3Locally Advanced or Metastatic GC and GCJ AdenocarcinomaOncologyAug 2028
NCT06682780LM-2417Phase 1Advanced Solid TumorOncologyDec 2028

Targets

CEACAM5 (1) CCR8 (1)

Companies with the same targets

Chongqing Precision Biotech Bristol-Myers Squibb Beijing Biotech Merck KGaA A2 Biotherapeutics Roche Genmab Harbour BioMed (Guangzhou) Kivu Bioscience Fortvita Biologics (USA)Inc.

Companies built like this

MediLink Therapeutics (Suzhou) Chipscreen Biosciences Servier Bio-Innovation Kumquat Biosciences Vividion Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.